Vaxcyte, Inc. Common Stock (PCVX) Financials
Key financial figures for Vaxcyte, Inc. Common Stock (Q2 2026).
Vaxcyte Inc. reported revenue of $0.00 for Q2 FY2026. The company posted a net loss of $284.3 million, or -$1.97 per share. Free cash flow for the period was -$532.5 million. The figures above are as filed, and the full income statement, balance sheet and cash flow history for Vaxcyte Inc. are on the SentiSense financials page.
- Revenue
- $0
- Net Income
- -$284M
- EPS
- $-1.97
- Total Assets
- $3.1B
- Operating Cash Flow
- -$232M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q2 FY2026 | $0 | -$284M | -$1.97 | -$532M | |
| Q1 FY2026 | $0 | -$321M | -$2.30 | -$295M | |
| Q4 FY2025 | $0 | -$247M | -$1.81 | ||
| Q3 FY2025 | $0 | -$213M | -$1.56 | -$155M | |
| Q2 FY2025 | $0 | -$167M | -$1.22 |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $0 | -$767M | -$5.63 | -$669M | |
| FY2024 | $0 | -$464M | -$3.80 | -$475M | |
| FY2023 | $0 | -$402M | -$4.14 | -$365M |
Frequently asked questions
What was Vaxcyte Inc.'s revenue last quarter?
Vaxcyte Inc. reported revenue of $0.00 for Q2 FY2026.
Is Vaxcyte Inc. profitable?
Not in its most recent reported period. Vaxcyte Inc. reported a net loss of $284.3 million for Q2 FY2026.
How much free cash flow did Vaxcyte Inc. generate?
Vaxcyte Inc. generated free cash flow of -$532.5 million in Q2 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Vaxcyte, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.